US FDA user fee bills progress in House
This article was originally published in Clinica
Executive Summary
A legislative package that would reauthorise the US Food and Drug Administration's authority to collect user fees from drug and device makers, and also create new user fee programmes for generics and biosimilar makers, has been cleared by the House energy and commerce committee with no trouble.